Sponsors / CADL
CADL

Candel Therapeutics, Inc.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
7Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaNCT00589875CADLPhase 2Completed2015-12Actual
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerNCT01436968CADLPhase 3Active not recruiting2024-08Actual
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaNCT02446093CADLPhase 2Unknown2025-12Estimated
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)NCT02768363CADLPhase 2Active not recruiting2024-11Actual
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCNCT04495153CADLPhase 2Active not recruiting2024-12-31Actual
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecNCT07332000CADLPhase 2Recruiting2027-02Estimated
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)NCT07660094CADLPhase 3Recruiting2031-10-22Estimated

Latest recorded trial changes

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

NCT07332000 · Candel Therapeutics, Inc.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Biodistribution of aglatimagene besadenovec; measure: Biomarkers of immune activation and tumor burden; measure: Biomarkers of immune activation and tumor burden; measure: Biomarkers of immune activation and tumor burden

+ Updated value

measure: Biodistribution of aglatimagene besadenovec

Check registry source · The saved outcome text may be shortened. Check the source for full wording.